PET/CT targeting prostate-specific membrane antigen (PSMA) has demonstrated an excellent ability to detect LNM prior to surgery [6, 8–11] and is widely used as a tool for staging before primary therapy restaging of PCa patients in the setting of biochemical relapse [8–10, 12]. Here, FOLH1 is linked to posterior cortical atrophy.